CJC-1295 (without DAC) (Modified GRF 1-29): Research Overview

What is CJC-1295?

Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 with DAC, this version preserves natural GH pulsatility without continuous elevation.

What is CJC-1295 researched for?

• Restores natural GH pulsatility patterns in aging individuals.
• Elevates IGF-1 through enhanced GH secretion.
• Supports pituitary axis without suppression of natural function.
• Supports maintenance of lean muscle mass through GH elevation.
• Supports bone health through GH-mediated pathways.
• Improvements in skin quality through collagen synthesis.
• Enhanced recovery from training through GH elevation.
• Improved sleep architecture with bedtime dosing.

How does CJC-1295 work?

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Reported targets: GHRH receptor

References

1. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog

   Jetté L, Léger R, Thibaudeau K, et al. · Endocrinology · 2005

   Identified CJC-1295 as a tetrasubstituted hGRF(1-29) analog that covalently binds albumin. Showed 4-fold increase in GH area under the curve compared to native hGRF(1-29) in rat pituitary cells.

   Animal study · PMID 15817669

2. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

   Teichman SL, Neale A, Lawrence B, et al. · The Journal of clinical endocrinology and metabolism · 2006

   Single injection of CJC-1295 produced dose-dependent 2- to 10-fold increases in GH for 6+ days and 1.5- to 3-fold increases in IGF-I for 9-11 days in healthy adults. Estimated half-life of 5.8-8.1 days.

   Early human study · PMID 16352683

3. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

   Ionescu M, Frohman LA · The Journal of clinical endocrinology and metabolism · 2006

   GH secretion was increased after CJC-1295 with preserved pulsatility. Basal (trough) GH levels were markedly increased (7.5-fold), demonstrating that CJC-1295 maintains natural GH pulse patterns.

   PMID 17018654

4. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse

   Alba M, Fintini D, Sagazio A, et al. · American journal of physiology. Endocrinology and metabolism · 2006

   Once-daily CJC-1295 maintained normal body composition and growth in GHRH knockout mice, demonstrating efficacy in restoring GH axis function in GH-deficient animal models.

   Animal study · PMID 16822960

5. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects

   Sackmann-Sala L, Ding J, Frohman LA, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009

   CJC-1295 administration in normal adults activated the GH/IGF-1 axis and produced measurable serum protein profile changes, providing biomarker evidence for sustained GHRH analog activity.

   PMID 19386527

Common questions